Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

BPC 157 given during reperfusion counteracts portal hypertension, caval hypertension and aortal hypotension in rats used to have portal triad obstruction (Pringle maneuver) (CROSBI ID 733680)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Kolovrat, Marijan ; Gojković, Slaven ; Krezić, Ivan ; Malekinušić, Dominik ; Drmić, Domagoj ; Horvat, Katarina ; Đuzel, Antonija ; Seiwerth, Sven ; Sikirić, Predrag BPC 157 given during reperfusion counteracts portal hypertension, caval hypertension and aortal hypotension in rats used to have portal triad obstruction (Pringle maneuver) // Gastroenterology (New York, N.Y. 1943). 2019. str. S-564-S-565 doi: 10.1016/s0016-5085(19)38304-0

Podaci o odgovornosti

Kolovrat, Marijan ; Gojković, Slaven ; Krezić, Ivan ; Malekinušić, Dominik ; Drmić, Domagoj ; Horvat, Katarina ; Đuzel, Antonija ; Seiwerth, Sven ; Sikirić, Predrag

engleski

BPC 157 given during reperfusion counteracts portal hypertension, caval hypertension and aortal hypotension in rats used to have portal triad obstruction (Pringle maneuver)

Aim. Reperfusion provokes major disturbances after Pringle maneuver. We revealed the stable gastric pentadecapeptide BPC 157 as the therapy of the hemodynamic disturbances after Pringle maneuver, temporary portal triad obstruction (PTO) (hepatic artery, portal vein, common bile duct occlusion for 30 min), BPC 157 given during reperfusion, in the post-PTO period. Previously, we noted in rats with PTO that BPC 157 may beneficially increase vessels branching in intestinal serosa and counteract intestinal lesions, counteract free radicals formation and most importantly, counteract portal hypertension and caval hypotension (Gastroenterology, 2017, Vol. 152, Issue 5, S909–S910 ; Gastroenterology, 2015, Vol. 148, Issue 4, S-650, Gastroenterology, 2015, Vol. 148, Issue 4, S-548). Methods: In deeply anesthetized and laparatomized rats that used to have PTO, the recording lasted 5 minutes with a cannula (BD Neoflon™ Cannula) (assessed in one minute intervals) connected to a pressure transducer (78534C MONITOR/ TERMINAL Hewlett Packard), inserted into the portal vein, inferior caval vein and abdominal aorta at the level of bifurcation at 24 h of reperfusion time. Medication (BPC 157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as an abdominal bath in rats used to have PTO, in post- PTO-period, at 1 min or at 24 h reperfusion time. Results: Continuous assessment of portal, caval and aortal pressure at the end of the PTO-period, PTO removal, and the immediate period thereafter showed that huge portal hypertension was still present while more caval hypertension simultaneously appeared and aortic pressure rose to values of 80 mmH. These hemodynamic disturbances persisted until the end of the experiment. Contrarily, when BPC 157 was given in those circumstances of the portal and caval hypertension, and arterial hypotension, these disturbances were completely eliminated (Fig.1, *P≤0.05, at least vs. control). This may be a particularly therapeutic advantage. Namely, caval hypertension was consistently elevated in comparison to portal hypertension, with a gradient of at least 10 mmHg. Some spontaneous decompression of the portal system can be hardly expected by a portocaval shunt. Thereby, if not therapy, the pressure of both the portal and the caval system remains elevated after removal of the portal clamp. Discussion/Conclusion. Thus, the effectiveness of the one challenge given at distinctive points during reperfusion appears as the conclusive evidence. BPC 157 therapy distinctively mitigates the whole syndrome involving the course of an even more complex model that should include rats clamped by the hepatic artery, portal vein, and bile duct vs. rats that used to have a clamped portal triad and later underwent reperfusion

portal triad obstruction ; reperfusion ; BPC 157

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S-564-S-565.

2019.

nije evidentirano

objavljeno

10.1016/s0016-5085(19)38304-0

Podaci o matičnoj publikaciji

Gastroenterology (New York, N.Y. 1943)

0016-5085

1528-0012

Podaci o skupu

Digestive Disease Week

poster

18.05.2019-21.05.2019

San Diego (CA), Sjedinjene Američke Države

Povezanost rada

Trošak objave rada u otvorenom pristupu

Temeljne medicinske znanosti

Poveznice
Indeksiranost